How to Order, Store, and Handle KENGREAL® (cangrelor)
Find your wholesaler to order and review storage guidelines
Supplied as a sterile lyophilized powder in single-use 10 mL vials, each containing 50 mg of KENGREAL.
- NDC 65293-003-01: 10 mL vial containing 50 mg of KENGREAL
Please use standard ordering procedure through your wholesaler by referencing the following:
If the product is not available at your wholesaler, your wholesaler can easily coordinate a drop shipment via Next-Day Saver from a Chiesi USA distribution provider.
Storing and handling KENGREAL
KENGREAL vials should be stored at USP Controlled Room Temperature [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted].1
See how KENGREAL is reimbursed
Download the Reimbursement Guide to learn more and view the HCPCS codes
IMPORTANT SAFETY INFORMATION
KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.
KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.
Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.
The most common adverse reaction is bleeding.
KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.